# AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

> **NCT00089674** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 1468 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** AMG 162
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00089674
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08-01
- **Primary completion:** 2008-05-16
- **Final completion:** 2010-05-11
- **Target enrollment:** 1468 (ACTUAL)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089674, "AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00089674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*